Adenosine receptor expression in rheumatoid synovium: a basis for methotrexate action
Arthritis Research & Therapy, 06/12/2012
Stamp LK et al. – The authors have shown that adenosine receptors are expressed in rheumatoid arthritis (RA) synovium. There is differential expression of receptors such that ADORA3 is expressed at significantly higher levels. This evidence demonstrates the potential for Methotrexate (MTX) to exert its anti–inflammatory effects at the primary site of pathology within the joints of patients with RA.
Adenosine receptor gene expression was undertaken using PCR in 20 rheumatoid arthritis (RA) synovial samples.
A separate cohort of 225 RA patients receiving MTX was genotyped for SNPs in the ADORA3 receptor gene.
Double immunofluorescence was used to identify cells expressing ADOR protein.
All ADOR genes were expressed in all synovial samples.
ADORA3 and A3variant were the dominant subtypes expressed irrespective of MTX therapy.
Expression of ADORA2A and ADORA2B was increased in patients receiving MTX compared to those not receiving MTX.
There was no association between the ADORA3 rs1544224 SNP and high and low disease activity or MTX–associated adverse effects.
ADORA2B protein expression was most obvious in vascular endothelial cells whereas ADORA3 protein was more abundant and expressed by synovial fibroblasts.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.